medigraphic.com
ISSN 1684-1824 (Electronic)

2019, Number 2

<< Back Next >>

Rev Méd Electrón 2019; 41 (2)

Insomnia disorder. Current considerations

Martínez HO, Montalván MO, Betancourt IY

Language: Spanish
References: 28
Page: 483-495
PDF size: 711.42 Kb.


ABSTRACT

Insomnia is the most frequently sleep disorder in the population. It is linked to a significant discomfort and an impairment of important areas of the human functioning. The correct diagnosis of this disorder is important with the objective of prescribing an adequate treatment for improving the life quality of the patients suffering it. The aim of this article is offering an up-dated review contributing to increase and update the information on this topic. The authors carried out a review of articles published mainly during the last five years, and the results were systematized for contributing to the professionals´ upgrading.


REFERENCES

  1. Medina-Chávez JH. Guía de práctica clínica. Diagnóstico y tratamiento del insomnio en el adulto mayor. Rev Med Inst Mex Seguro Soc [Internet]. 2014 [citado 23/04/2017];52(1):108-19. Disponible en: http://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=47619

  2. Morin C, Leblanc M, Daley M, et al. Epidemiology of insomnia: prevalence, selfhelp treatments, consultations, and determinants of help-seeking behaviors. Sleep Med. 2006; 7(2):123-30.Citado en PubMed:PMID:16459140

  3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders [Internet]. 5ª ed. (DSM-5). Washington, DC: American Psychiatric Assotiation [citado 23/12/2018]; 2013. Disponible en: https://www.psychiatry.org/psychiatrists/practice/dsm

  4. Medrano-Martínez P, Ramos-Platón MJ. Alteraciones cognitivas y emocionales en el insomnio crónico. Rev de Neurología. 2016;62(4):170-78.Citado en PubMed: PMID: 26860722.

  5. Leger B, Bayon V, Ohayon MM, et al. Insomnia and accidents: cross-sectional study (EQUINOX) onsleep-related home, work and car accidents in 5.293 subjects with insomnia from 10 countries. J J Sleep Res 2014;23(2):143-52. Citado en PubMed:PMID:24237855

  6. American Academy of Sleep Medicine. The International Classification of Sleep Disorders–Third Edition(ICSD-3) [Internet].American Academy of Sleep Medicine[citado 23/11/2018];2014. Disponible en: https://journal.chestnet.org/article/S0012-3692(15)52407-0/fulltext

  7. Ohayon MM, Riemman D, Morin C, et al. Hierachy of insomnia criteria based on dattime consequences. Sleep Med. 2012;13(1):52-7. Citado en PubMed:PMID:22036602

  8. Baglioni C, Battagliese G, Feige B, et al. Insomnia as a predictor of depression: a meta analytic evaluation of longitudinal epidemiological studies. J Affect Dis. 2011;135(1-3):9-10. Citado en PubMed:PMID:21300408

  9. Insomnia DynaMed Plus®:the next-generation clinical information resource designed to decrease time to answe[Internet]. España:Try DynaMed Plus today [citado 23/11/2018];1995. Disponible en: https://dynamed.com/home/

  10. Siebern AT, Suh S, Nowakoski S. Non-pharmacological treatment of insomnia. Neurotherapeutics 2012;9:717-27. Citado en PubMed:PMID:22935989.

  11. González CA, Alonso Álvarez ML, Cañellas Dols F, et al. Pautas de actuación y seguimiento del insomnio Fundación para la Formación de la Organización Médica Colegial de España. España: Organización Médica Colegial de España; 2016.

  12. Hartescu I, Morgan K, Stevinson CD. Increased physical activity improves sleep and mood outcomes in inactive people with insomnia: a randomized controlled trial. J Sleep Res. 2015;24(4):526. Citado en PubMed:PMID:25903450.

  13. Tan X, Alén M, Wiklund P, et al. Effects of aerobic exercise on home-based sleep among overweight and obese men with chronic insomnia symptoms: a randomized controlled trial. Sleep Med. 2016;25:113. Citado en PubMed:PMID:27823703.

  14. Hysing M, Pallesen S, Stormark KM, et al. Sleep and use of electronic devices in adolescence: results from a large population-based study. BMJ Open 2015; 5: e006748. Citado en PubMed:PMID :25643702.

  15. Beaulieu-Bonneau S, Ivers H, Guay B, et al. Long-Term Maintenance of Therapeutic Gains Associated With Cognitive-Behavioral Therapy for Insomnia Delivered Alone or Combined With Zolpidem. Sleep. 2017;40(3). Citado en PubMed:PMID :28364426.

  16. Álamo C, López-Muñoz F, García-García P. Exploring new frontiers for the pharmacological treatment of insomnia. Clin Exp Pharmacol [Internet]. 2014[citado 23/11/2018];4(5):1.000e133. Disponible en: https://www.omicsonline.org/openaccess/ exploring-new-frontiers-for-the-pharmacological-treatment-of-insomnia- 2161-1459-e133.php?aid=32958

  17. Aguilar Gomez B. Ramelteón. Un fármaco para la lucha contra el insomnio [Internet]. MoleQla .revista de Ciencias Universidad Pablo de Olavide[citado 23/11/2018]. 2018(29):32-35. Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=6449717

  18. Qaseem A, Kansagara D, Forciea MA, et al. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2016;165. Citado en PubMed:PMID:27136449

  19. Billioti de Gage S, Moride Y, Ducruet T, et al. Benzodiazepine use and risk of Alzheimer’s disease: case-control study. BMJ. 2014; 349:g5205. Citado en PubMed:PMID:25208536.

  20. Álamo C, García- García P, López-Muñoz F. Estudios clínicos de melatonina en los trastornos del sueño. Papel diferencial de melatonina de liberación prolongada. Kranion [Internet]. 2014 [citado 23/12/2018];11(2):93-112.Disponible en:http://www.kranion.es/resumen.asp?id=182&indice=2014112

  21. Weich S, Pearce HL, Croft P, et al. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ [Internet]. 2014 [citado 22/11/2018];348:g1996. Disponible en: https://www.bmj.com/content/348/bmj.g1996

  22. Álamo C. Polifarmacia y fragilidad. Interacciones, Reacciones Adversas Medicamentosas y seguridad de los fármacos. En: Guía de buena práctica clínica en Geriatría. Madrid: SEGG; 2015.

  23. European Medicines Agency. Assessment report for Circadin [Internet]. Amsterdam: EMA [citado 22/11/2018];2007. Disponible en: https://www.ema.europa.eu/en/medicines/human/EPAR/circadin

  24. Wade AG, Farmer M, Harari G, et al. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer’s disease: A 6-month, randomized, placebo-controlled, multicenter trial. Clin Interv Aging. 2014;9:947- 61. Citado en PubMed:PMID:24971004

  25. Hajak G, Lemme K, Zisapel N. Lasting treatment effects in a postmarketing surveillance study of prolonged-release melatonin. Int Clin Psychopharmacol. 2015;30(1):36-42. Citado en PubMed:PMID:25054634

  26. López Trigo JA, González P, Merino M, García P. En: Álamo C, Gil Gregorio P (eds.). Guía de Buena Práctica Clínica en Geriatría: Insomnio. Madrid: Sociedad Española de Geriatría y Gerontología (SEGG);2015.

  27. Shah C, Sharma TR, Kablinger A. Controversies in the use of second generation antipsychotics as sleep agent. Pharmacol Res. 2014;79:1-8. Citado en PubMed:PMID:24184858.

  28. D'Hyver de las Deses C. Alteraciones del sueño en personas adultas mayores. Rev Fac Med Méx[Internet]. 2018 [citado 22/11/2018];(61):1. Disponible en: http://www.medigraphic.com/pdfs/facmed/un-2018/un181e.pdf




2020     |     www.medigraphic.com